Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amphastar Pharma (NQ: AMPH )

49.78 +1.14 (+2.34%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 599,048
Open 48.59
Bid (Size) 48.00 (3)
Ask (Size) 51.00 (5)
Prev. Close 48.64
Today's Range 48.30 - 50.23
52wk Range 36.56 - 65.92
Shares Outstanding 48,675,822
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva, Organon, and Viatris. 
Via Benzinga
Amphastar Pharmaceuticals to Present at the 2024 Wells Fargo Healthcare Conference
Via ACCESSWIRE

Performance

YTD
-20.08%
-20.08%
1 Month
+6.39%
+6.39%
3 Month
+24.29%
+24.29%
6 Month
+11.69%
+11.69%
1 Year
+7.68%
+7.68%

More News

Read More
AMPH Stock Earnings: Amphastar Pharma Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2024
Via ACCESSWIRE
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7, 2024
Via ACCESSWIRE
Why the growth investor may take a look at NASDAQ:AMPH.
Via Chartmill
Exploring NASDAQ:AMPH's growth characteristics.
Via Chartmill
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2024
Via ACCESSWIRE
NASDAQ:AMPH, an undervalued stock with good fundamentals.
Via Chartmill
7 Biotech Stocks to Buy on the Dip: June 2024
Via InvestorPlace
Top 2 Small Cap Healthcare Stocks to Buy Before Rate Cuts
Via MarketBeat
Topics ETFs Economy
Exposures Interest Rates
Amphastar Announces Additional $50 Million Increase to its Share Buyback Program
Via ACCESSWIRE
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Via ACCESSWIRE
Amphastar Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol
Via ACCESSWIRE
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2023
Via ACCESSWIRE
Delving into NASDAQ:AMPH's Growth Prospects.
Via Chartmill
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
Amphastar Pharmaceuticals to Present at the Bank of America Securities Health Care Conference
Via ACCESSWIRE
AMPH Stock Earnings: Amphastar Pharma Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 8, 2024
Via ACCESSWIRE
Earnings Outlook For Amphastar Pharma
Via Benzinga
Amphastar Pharmaceuticals Interested In Potential Acquisitions In Endocrinology-Focused Companies
Via Benzinga
Amphastar Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
Via ACCESSWIRE
Amphastar Pharmaceuticals to Present at the Barclays 26th Annual Global Healthcare Conference
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.